How $NVO makes money
https://x.com/Mayhem4Markets/status/1821873933919912300
Second forecast cut of 2025.
The obesity drugmaker warned that both full-year sales and operating profit would grow significantly less than previously expected, citing weaker demand projections for its blockbuster weight-loss drug Wegovy and diabetes treatment Ozempic.
The company now expects sales growth of just 8%-14% in local currencies.
Operating profit growth projections were similarly downgraded to 10%-16%.
The company cited “lower growth expectations for Wegovy in the U.S. obesity market” and “lower growth expectations for Ozempic in the U.S. GLP-1 diabetes market” as primary drivers of the reduced outlook.
Users browsing this forum: No registered users and 2 guests